1. Introduction
Atherosclerosis (ATH) is a condition characterized by thickening of the arterial intima as a result of the accumulation of fatty materials (mainly cholesterol and cholesterol esters). Lesions of the disease (atheromas or atherosclerotic plaques) have three distinct components, (1) the atheroma which is the nodular accumulation of a soft, flaky yellowish material at the center of the large plaques, composed of macrophages nearest the lumen of the artery, (2) underlying accumulations of cholesterol crystals, and (3) calcification of the older or more advanced lesions. In human beings, ATH is major cause of adult mortality in the developed world [1]. In animals, ATH occurs rarely, and only infrequently leads to a clinical disease such as infarction of the heart and brain. Several studies have indicated that the pig, rabbit, and chicken are susceptible to experimental induction of the disease through feeding of a high- cholesterol diet and that the dog, cat, cow, goat, and rat are resistant. Naturally – occurring disease has been reported in aged pigs and birds and in dogs suffering from hypothyroidism that accompanies hypercholesterolemia [2].
The smooth muscle cells (SMCs) constitute the predominant cellular element of the vascular media, cause vasoconstriction or dilation in response to physiological or pharmacological stimuli, synthesize extracellular matrix (collagen, elastin and proteoglycans); elaborate growth factors and cytokines; and migrate to the intima and proliferate after vascular injury. These activities of SMCs are important in both normal vascular repair and pathological processes such as ATH. Physiological regulation of the migratory and proliferative activities of the SMCs is regulated by growth promoters and inhibitors. Among the promoters are the platelet – derived growth factor derived from platelets (and endothelial cells and macrophages), basic fibroblast growth factor, and interleukin 1. Inhibitors include heparin sulfates, nitric oxide, interferon γ, and transforming growth factor β.
Injury of the wall of blood vessels stimulates SMCs growth by disrupting the physiological balance between inhibition and stimulation. Repair of the injured vascular wall constitutes a physiologic healing response with the formation of a neointima, in which SMCs: (1) migrate from the media to the intima, (2) proliferate as intimal SMCs, and (3) elaborate extracellular matrix. During the healing process, the SMCs in the intima lose the capacity to contract and gain the capacity to divide. Within the intima, the SMCs may return to the nonproliferative state when either the overlying endothelial layer is re – established after acute injury or the chronic inflammation ceases. However, intimal thickening occurs when the healing response is exaggerated and this can cause stenosis or occlusion of small and medium sized blood vessels.
2. Functional roles of VSMC in atherosclerosis
Functional roles of VSMC in atherosclerosis include: (1) phenotypic switching (from quiescent "contractile "phenotype to active "synthetic "state; (2) extracellular matrix (ECM) deposition; (3) proliferation; (4) migration; (5) inflammatory gene expression, (6) oxidant stress; and (7) monocyte retention (monocyte – VSMC binding) (Figure 1).
2.1. Phenotypic switching
Several studies demonstrated that the vascular smooth muscle cells have phenotypes that differ in the media and atherosclerotic lesions, and that phenotypic switching of SMCs plays a central role in atherosclerosis according to Ross's hypothesis [3, 4]. It has been proposed that before migration from the media into the intima, a transition of the SMCs phenotype is required [5]. In the media, the SMCs have a contractile phenotype that enables them to regulate the vascular tone. When these cells proliferate they acquire a synthetic phenotype. During the proliferative state the SMC requires extensive changes in gene expression and protein synthesis [6].
A major challenge in understanding differentiation of the SMCs is their ability to appear as a wide range of different phenotypes at different stages of development, and even in adult organism the cells are not terminally differentiated and are capable of major changes in their phenotype in response to changes in their local environment [7, 8, 9]. During early stages of vasculogensis SMCs are highly migratory and undergo rapid cell proliferation. Many studies indicated that there is a remarkable amount of movement of SMCs and SMC progenitor cells as part of the complex morphogenic events that leads to the formation of the cardiovascular system [10, 11]. During vascular development, SMCs also show high rate of synthesis of extracellular matrix components including collagen, elastin, proteoglycans, cadherins, and integrins that share the formation of blood vessel mass. In this stage of development, SMCs form abundant gap junctions with endothelial cells, and the process of investment of endothelial tube with SMCs or pericytes is necessary for vascular maturation and vessel remodeling [12]. In comparison, the SMCs in adult blood vessels show very low rate of proliferation turnover, are largely nonmigratory, show a very low rate of synthesis of extracellular matrix components, and are committed only to carry their contractile function [9]. Mature fully differentiated SMCs express a repertoire of appropriate receptors, ion channels, signal transudation molecules, calcium regulatory protein, and contractile protein [7]. Following vascular injury the "contractile" SMCs are capable of undergoing transient modification of this phenotype to a highly "synthetic ' phenotype, and they play an important role in the repair of vascular injury. However, that repair of vascular injury is carried out principally (or exclusively) by reversible phenotype modulation of preexisting SMCs is a matter of controversy. Many studies proposed two alternative mechanisms although in reality none is mutually exclusive. In the first one there is evidence that the circulating bone marrow derived SMC progenitor cells play a major role in the repair of vascular injury [13, 14, 15]. The second proposed mechanism is supported by the evidence that SMC populations within blood vessels are extremely heterogeneous with resident stable populations of preexisting SMCs that are phenotypically distinct from the classical definition of a contractile SMCs [16, 17] and that these cells accomplish the injury repair [9].
Some recent studies have provided evidence that circulating cells, presumably derived from bone marrow, can contribute to neointima formation and repair of vascular injury [13, 15, 18]. However, these studies involved very extensive damage to medial SMCs (almost complete destruction of the media and SMCs death), and / or immunologic injury due to genetic mismatch of host and donor tissues following tissue transplantation combined with lack of adequate immunosuppression therapy. However, there is no single study in the severe mechanical injury models have provided strong evidence that bone marrow cells within lesions express definitive SMC markers such as smooth muscle (SM) myosin heavy chain (MHC) and smoothelin. In addition no studies have been made on the possibility of fusion of circulating progenitor cells with resident SMCs [9].
A number of studies are available demonstrating that there are heterogeneities between SMCs within the blood vessel with retention of a resident stable population of cells that have a "synthetic phenotype" [17, 19]. In the study of [19] a panel of antibodies specific for different markers of SMC differentiation including SMC α – actin, SM MHC, calponin, desmin, and meta – vinculin were used to perform immunofluorescence labeling studies on cryosections of adult and fetal bovine main pulmonary arteries. The authors performed also Western analyses of these marker genes in the three different layers of the adult bovine pulmonary artery. These authors reported the presence of four distinct populations or clusters of MSCs based on morphology, cell orientation, pattern of elastic lamellae, and immunostaining patterns and proposed that these populations may represent unique lineages performing different functions within the arterial media, and respond in different ways to stimuli. Although strong evidence exists for the presence of heterogenous populations of SMCs in vivo no studies were done to demonstrate that these represent distinct stable SMC lineages that play a preferential role in carrying out repair of vascular injury in vivo. The studies of Clowes and co-workers [20, 21, 22] would seem to refute such a possibility in that they showed SMC growth fractions (the fraction of medial SMC at time O that leave Go and reenter the cell cycle) of up to 60% following balloon injury of the rat carotid artery, indicating that the majority of SMCs within the media possess the ability to reenter the cell cycle and contribute to repair of vascular injury in adult animals. Thus the preexisting "subpopulation "of SMC capable of phenotypic switching is much greater than frequencies reported by [19] and represent a large fraction of SMCs in the vessel wall. [23] using the generation of complex SMC ancestor tables for the entire SMC population within the thoracic and abdominal aorta based on pulse – chase labeling with [3H] thymidine in hypercholesteremic swine models of atherosclerosis provided evidence that supports the previous findings. They found that the intimal lesions were polyclonal and derived from multiple histologically discrete medial SMCs that initiated DNA replication and subsequently underwent several rounds of DNA replication. These findings are in discrepancy with a model in which only a small fraction of medial SMCs contribute to lesion formation.
Results of another study [24] reported that distinct populations of rat cultured SMCs (adult and embryonic) when implanted into a rat carotid artery in vivo retained some phenotypic differences. These findings suggest that there is considerable stability in the phenotype of these cells. However, it is possible that the stable epigenetic reprogramming of these cells was a function of their extensive growth in culture. Additionally, since large number of cells were transplanted, it is possible that the transplanted cells could created their own "microenvironmental domain or milieu "and that autocrine and paracrine effects contributed to the retention of phenotypic differences. [25] suggested the existence of a subpopulation of terminally differentiated SMC that is incapable of cell cycle reentery. Evidence for this suggestion was based on studies showing failure of a subpopulation of SMC derived from dog aorta to proliferate in culture. However, this finding may repersent the lack of appropriate culture reagents and / or conditions necessary to support growth of these cells.
In summary, it seems that the principal source of SMCs responsible for repair of vascular injury under "normal "circumstances are the preexisting SMCs that undergo transient and reversible phenotypic modulation. However, circulating bone marrow cells, cells derived from the adventitia, and / or preexisting subpopulations of phenotypically modified SMC can participate to some extent as well. The role of each of these different populations differs according to the nature of the vascular injury or the disease state.
2.2. ECM deposition
ECM comprises > 50 % of the atherosclerotic lesion and it consists of a mixture of vastly different macromolecules including collagen, elastin, glycoproteins, fibronectin, laminin, vitronectin, and thrombospondin. These matrix proteins are produced largely by the activated VSMCs [26, 27] and confers tensile strength and viscoelasticity to the arterial wall. Each of these ECM components possesses unique structural properties that determine its own roles during the development of atherosclerotic plaques. In addition to its role in supporting the plaque, ECM participates in many key events such as cell migration and proliferation, lipoprotein retention and thrombosis.
Matrix metalloproteinases (MMPs) are endopeptidases produced by SMCs and macrophages and they contribute significantly to the degradation and remodeling of the plaque extracellular matrix [29]. MMps that are induced to be expressed by environmental factors present within the lesion can actively modify the matrix in which SMCs reside and actively contribute to further phenotypic switching of the SMC. SMC phenotype is prone to modification by a number of factors including PDGF [30], TGF β [31], intric oxide [32], and reactive oxygen species [33]. These factors have been demonstrated to modify MMP production in cultured SMCs, although information concerning the mechanisms and factors that control expression of MMPs in vivo are still lacking. A major determinant of plaque stability is the existence of a balance between production of matrix degrading MMPs, the inhibitors MMPs or tissue inhibitor of metalloproteinase (TIMPs), and matrix production by SMCs [34, 35]. In normal arteries of human and laboratory animals, MMP – 2 (72 – Kda gelatinase) and TIMp – 1 and TIMP – 2 are constitutively expressed at levels creating a stable balance between endogenous matrix proliferation and matrix degradation m and a normal MMP – to – TIMP ratio [29]. In the developing atherosclerotic lesion, this ratio is tipped towards MMPs as described in part by an increase in MMP – 3 (stromelysin) and MMP – 9 (92 – Dka gelatinase), and increased MMP – to – TIMP ratio [29]. It would seem that MMP overexpression is important for the migration and formation of a SMC – rich fibrous plaque and subsequent plaque stabilization. Galis
2.3. SMC proliferation
Immediately following activation by the injury, growth factor, or cytokine, the SMC undergoes phenotypic change that leads to a migratory and secretory cell that migrates into the neointima [41]. Stimulation by growth factor or cytokine causes the SMCs to proliferate and secrete matrix proteins and enzymes. Whereas the complex atherosclerotic lesions contain a mixed type of cells including SMCs, lipid laeden macrophages, and lymphocytes, the vascular SMCs are the dominant cellular component of the de novo and in-stent restenotic lesions. Results of both experimental and randomized clinical trials have shown that significant retardation of in-sent stenosis could be achieved through the delivery of inhibitors of inflammation and of SMCs proliferation such as sirolimus and paclitaxel to the site of intervention on drug – eluting stents [42, 43].
Proliferative phenotype of vascular SMCs in both physiological and pathological events involve critical changes in the gene expression patterns of the proliferating cells. Growth- promoting factors such as angiotensin 11 or oxidized low density lipoprotein stimulate the vascular SMCs and lead to increased expression of genes coding for iron transporters, extracellular matrix components, cell – cell adhesion molecules, cytoskeletal proteins, transcription factors and cell cycle regulatory proteins [44, 45]. Comparison between the healthy vascular SMCs and vascular SMCs isolated from various disease conditions, such as primary atherosclerosis and in – stent stenosis reveals similar changes in gene expression patterns [46].
Changes in gene expression programs are influenced largely by transcriptional events, but the contribution of posttranscriptional events (such as mRNA processing, transport, turnover, and translation) is becoming increasingly recognized [47]. One of the most important of these events, stability of regulated mRNA critically contributes to the implementation of gene expression patterns during the cellular response to mitogens, immunological triggers, stress, and differentiation agents [48, 49]. A growing list of proteins central to the execution of such responses (P21, Hsp70, MnsoD, catalase, Cdc25, cyclin A, cyclin B1, c-Fos, c-Jun, c-Myc, Egr-1, etc) are encoded by labile mRNA, which have tightly regulated half – lives [47].
Among the well – studied determinants of transcript stability are U – rich or A + U rich elements (collectively termed AREs) generally present in the 3' -untranslated regions of labile mRNA [50]. Several RNA – binding proteins have been found to bind to AREs and leads to transcript decay and they include BRF1, AUF1, and KSRP [51, 52, 53]. HuR, a member of the Hu / ELAV protein family binds to AREs and instead promote transcript stabilization. HuR stabilizes many mRNAs that encode growth factors, cell division proteins, and cytokines. An important role of HuR during the response to immune factors and proliferate signals has been described in many cell systems [54, 55, 56, 57, 58].
HuR was found to regulate cell proliferation in a mouse model of skeletal muscle development and regeneration, purportedly through its effect on the expression of proteins governing cell growth and differentiation [59, 60]. Pullmann, Jr.
In summary, the migratory and proliferative activities of VSMCs are regulated by a balance between growth promoters such as platelet derived growth factors (PGF), endthelin – 1 (ET – 1), thrombin, fibroblast growth factor (FGF), interleukin -1 (IL - 1) and inhibtors such as, heparin sulfates, intric oxide (NO), transforming growth factor (TGF) – beta. A role has been suggested for matrix metallo – proteinases (MMPs) could catalyze and remove the basement membrane around VSMC and facilitate contacts with the interstitial matrix. VSMCs are stimulated to proliferate and migrate by some kinds of cytokines, growth factors, and angiotensin II (Ang – II). Apoptosis, proliferation and migration of VSMCs are essential features of the pathogenesis of atherosclerosis and plaque rupture. Rupture of the plaque is associated with increased number of fibrous cap macrophages, increased VSMC apoptosis and reduced fibrous cap VSMCs. Within the plaques, the VSMCs are the only cells capable of synthesizing structurally important collagen isoforms, and the apoptosis of VSMC might promote plaque rupture [63].
2.4. SMC migration
Agents that induce VSMC migration include growth factors (Angiotensin II, PDGF, bFGF, HB – EGF, IGF – 1, VEGF, Thrombin), cytokines / chemokines (IL – 1 β,. IL – 6, TL -6, TFβ 1, TNF – alpha, MCP – 1), extracellular matrix components (collagen 1, IV, collagen VIII, fibronectin, hyaluronan, laminin, osteopontin thrombospondin, vitronectin), bioactive lipids (LPA, Hydroxyeicosatrienoic acids [12 or 15 (s) – HETE ], diabetogenic agents [ high glucose (25 mmol / L) ], advanced glycation end products (AGEs), RAGE ligands S 100 B, and other molecules (ATP, UTP, norepinephrine, histamine, and serotonin) [64]. Angiotensin II – induces VSMC migration through P38 – MAPK activated c – Src through two distinct but redundant pathways, one via Syk, and other via EGFR transactivation through ERK 1/2 and partially through p38 MAPK [64]. Receptor for advanced glycation end products (RAGE) ligands induce inflammatory genes and VSMC migration via Src kinase [64]. Additionally, RAGE ligand (S100B) activates Src and MAP kinases in VSMCs [64]. In diabetic db / db mice, it has been found that there was enhancement of RAGE expression, Src activation, and migration in VSMCs [64].
2.5. Inflammatory gene expression
The atherogenic cytokines that are released from SMCs, endothelial cells (EC), macrophages, T lymphocytes, and B lymphocytes include IFN (released from SMC, macrophages, T lymphocytes, and causes increased SMC migration and proliferation, increased ECM remodeling, and increased adhesion molecule expression), IL – 1 (released from SMCs, EC, macrophages, and T and B lymphocytes and increases SMC migration and proliferation, monocyte accumulation, and adhesion molecule expression), IL – 18 (released from SMC, EC, and macrophages, and causes increased adhesion molecule expression, increased SMC accumulation, and ECM remodeling), MCP – 1 (produced by the SMC, EC, macrophages, and T lymphocytes, and increases recruitment of monocytes, SMC migration and ECM synthesis and remodeling), PDGF – BB (produced by the SMC, EC, and macrophages, and increases SMC migration and increases SMC migration anf proliferation), and TGFβ (elaborated by SMC, EC, macrophages, and proliferation and increases SMC migration and proliferation, and ECM synthesis) [64]. Cytokines that are involved in atherogenesis include TNF – α, IL – 1, IL – 6, IL – 8, IL – 12, IL – 15. IL – 18, IL 32, and MCP – 1 produced by macrophages under the influence of resisting leptin, and adiponectin elaborated from adipose tissue. Cytokines released from macrophages stimulate SMC to produce the cytokines TNF – α, IL – 1, IL – 6, and IFN – (?). Those same cytokines also activate the EC to prduce VCAM – 1, ICAM – 1, E – selectin, P – selectin, IL – 1, IL – 6, IL – 8, IL – 18, IL PB, and MCP – 1. Other cytokines also produced by Tho (IL – 2, IL – 3), Th 1 (IL – 2, INF, IL – 17) Th 2 (IL – 4, IL – 5 < IL – 6, IL – 10, IL – 13), Treg (IL – 10, TGFβ), NKT cells (IFN), and macrophages (IL – 10, TGFβ, IL – lra, IL – 18BP) [64].
2.6. Oxidative stress
An important feature of the pathological porcess in atherogenesis is an increased generation of reactive oxygen species (ROS). All components of the atherosclerotic lesion has been shown to increase production of ROS mainly superoxide anion (O2-) [26, 65]. The ROS are produced by the VSMCs, endothelial cells, fibroblasts, and infiltrating leukocytes [66]. These ROS affect gene transcription, damages DNA, and increases production of inflammatory transcription factors [67]. Oxidation of LDL and scavenging of endothelium – derived NO are the best studied effects [26].
The mechanism of oxidative modification of LDL is unknown but there is always oxidized LDL in atherosclerotic lesions. Experimental studies indicated that the level of oxidized LDL, as measured by autoantibody titers, is reflective of the atherosclerotic burden [68]. Many of the atherogenic processes are induced by the oxidized LDL and these include transcription of proatherogenic genes, production of matrix metalloproteinases and tissue factor, antagonism of endothelial cell production of NO, and promotion of VSMC apoptosis [69]. The increased production of superoxide anion rapidly reacts with NO to produce peroxynitrite, a potent oxidant [70]. It has been stated that scavenging of NO increases inflammation, platelet activation, and vasoconstriction [26].
Studies of antioxidant vitamins, including the Guppo Italiano per 10 Studio della Sopravvivenza nell' Infarto myocradico (GISSI) Prevention Trial, the Heart Outcomes prevention Evalution Study (HOPE), and the Heart protection Study (HPS), did not show any reduction in clinical events with antioxidant vitamin E therapy [71, 72]. However, in these trials there were limitations that precluded the adequate test of the hypothesis ([73]. One of these limitations is that the rate constant for reaction of vitamin E or C with superoxide anion is much slower than for superoxide anion with NO or endogenous antioxidant enzymes [74]. Oral intake only slightly increases the levels of vitamin in plasma and tissue, and this may not affects the events in the vascular wall, where it is not concentrated. Vitamin E contributes little in the form of antioxidant protection in the cytoplasm, nucleus, or interstitial space since it is concentrated in the lipid bilayers. Additionally, a delay in treatment may have abolished its effect on the development of lesions and with little effect on plaque rupture and clinical events. However, some other therapeutic studies in the same trials (e.g. HOPE and HPS) indicated significant benefit [67, 75]. Of equal importance is that conventional antipletlet therapy has antioxidant effects as it has the ability to limit ROS production by activated platelets. The fact that oxidative stress plays important role in the pathogenesis of atherosclerosis makes clear that the limitations of current therapies should not conclude therapeutic interest in this area but stimulates studies into new ways of treatment.
2.7. Monocyte – VSMC binding
Monocytes in circulation adhere and migrate across the endothelium in response to atherogenic stimuli. Initially, these processes may be reversible, whereas subsequent accumulation and retention of monocytes – macrophages into the intima become a central pathogenic process in atherogenesis [76]. The mechanisms by which the monocytes are retained in the subendothelium and the role of VSMCs in this process are not known. Adhesive reactions between marginated monocytes and VSMCs have been proposed to contribute to monocyte- macrophage retention in the intima. Evidence for the possible interaction between VSMCs and the monocytes comes from the fact that VSMC express adhesion molecules within the atherosclerotic lesions but not in normal vessels [77]. In addition, a highly significant association was demonstrated between VSMC vascular cell adhesion molecule (VCAM) – 1 expression and the content of the intimal macrophage [78, 79]. Furthermore, a significant focal expression of intercellular adhesion molecule (ICAM) – 1 on VSMC in regions prone to atherosclerosis was found preceding mononuclear cell infiltration in man, which indicates a causative role in lesion development [80]. It has been shown that cell – to – cell interactions between monocytes and VSMC enhanced the procoagulant activity of monocytes and increased the production in both cell types of atherosclerosis – related materials such as metalloproteinase – 1 [81]. These findings indicated that the VSMCs and monocytes – macrophages are not merely neighbors in the vessel wall but that VSMC – monocyte interactions constitute additional signals in the pathogenesis of atherosclerosis. However, the cellular, molecular, and signal transudation mechanisms need to be elucidated.
A well-known fact is that angiotensin II (ANG II) and platelet – derived growth factor (PDGF) – BB have a significant role in vascular remodeling and atherosclerosis [82]. They are capable of inducing VSMC migration, hypertrophy, and proliferation [82, 83]. Cai
3.VSMCs in the pathogenesis of atherosclerosis
3.1. Humans
Three major types of cells that are commonly seen in the atherosclerotic lesions are the SMCs (which dominates the fibrous cap), macrophages (inflammatory cells) that infiltrate around the necrotic core, and the lymphocytes (intracellular and intercellular lipid) which have been mainly ascribed to the fibrous cap [85, 86]. A very complex interplay exists between these cells in the various developmental stages of the atherosclerotic lesion. This complex interrelation is further complicated by a number of risk factors that contribute to the clinical manifestation of the disease, and they include the abnormal vasomotor function, the thrombogenicity of the blood vessel wall, the state of activation of the coagulation cascade, the fibrinolytic system, SMC migration and proliferation, and inflammation process [76, 86, 85]. However, the exact cause of development of the atherosclerosis is not completely understood. Similarly much more information is needed concerning regulation of the key role of SMCs in vascular injury repair and in the development and / or progression of atherosclerosis. Finally, additional work is needed to clarify the specific contributions of the SMC versus other cell types within the lesion, such as macrophages and endothelial cells, to the end-stage clinical sequelae of atherosclerosis including plaque rupture, thrombosis, infarction, vasospasm, myocardial ischemia, and death.
3.2. Birds
Various avian species such as pigeons [87, 88], turkeys [89], and chickens [90] have been shown to be the convenient experimental animals for induction of atherosclerosis. Shih
Fabricant and Fabricant [102] investigated the roles of both Marek's disease herpesvirus (MDV) and dietary cholesterol in atherosclerosis in chickens. The birds were examind 7 months after MDV infection with and without cholesterol feeding for gross and microscopic arterial lesions. Typical lesions of atherosclerosis were observed only in infected normocholesterolemic or hypercholesterolemic birds. They were not detected in uninfected birds even if the birds were hypercholesterolemic. Furthermore, immunization with turkey herpesvirus vaccine or SB – 1 vaccine prevented atherosclerotic lesions. Hajjar
Spontaneous atherosclerosis is of common occurrence in captive parrots [104]. It occurs in all parrot species but with the highest occurrence in African Grey parrots and Amazons. Old birds are more commonly affected, and the disease has been seen in both males and females. Sudden death is the most common signs, but clinical symptoms include dyspnea, lethargy and nervous sign, such as paresis and collapses. Atherosclerosis is mostly an unexpected finding at necropsy because clinical signs of the condition are seldomly seen and the difficulty associated with diagnosis. In parrots, age and species are determinants of atherosclerosis. Risk factors have been suggested to include an elevated plasma cholesterol level, diet composition, social stress, and inactivity [104]. Frick
3.3. Pigs
In recent years an increase occurred in use of pigs as a promising species for morphological, biochemical, and metabolic studies of cardiovascular diseases particularly atherosclerosis [106, 107, 108]. Anatomy and physiology of the cardiovascular system of pigs resemble that of man. Among the similarities are size and distribution of arteries, location of thickened intima in the normal state, blood pressure, heart rate, plasma lipoprotein patterns, and responses to diets rich in fat and cholesterol [108]. Spontaneous atherosclerosis is known to develop in pigs with increased age, and have lipoprotein profiles and metabolism similar to humans [106, 107]. Use of high fat, high cholesterol diets in pigs leads to elevation of total and LDL plasma cholesterol [106]. Several studies have shown the ability to induce aortic lesions in pigs very similar to those seen in human atherosclerosis disease [106].
3.4. Rabbits
Among animals that have been used as models for experimental atherosclerosis, the rabbit is the only one that has the tendency to exhibit hypercholesterolemia within a few days of administration of a high cholesterol diet [110, 111]. Furthermore, the late stages lesions of human atherosclerosis are similar to those caused in rabbits when a diet low in cholesterol is administered for extended periods [110]. More advanced lesions in the thoracic and abdominal aorta, could be induced in rabbits through a high cholesterol diet can be combined with a single or double balloon injury. Balloon injury enhances the formation of atheromatic lesions and leads to the production of plaques with a lipid core covered by a fibrous cap with a high amount of SMCs. Such lesions are more similar to human atherosclerotic lesions than those produced by feeding rabbits with a high cholesterol diet alone [37, 112].
Hypercholesterolemia that is induced in rabbits through diet is caused by the accumulation of exogenous cholesterol. Rabbits cannot increase the excretion of sterols and this explains their high susceptibility to inducement of atherosclerosis [113]. Consequently, increased quantities of lipoproteins rich in cholesterol esters enter the blood circulation. LDL and β – VLDL are the main transporters of cholesterol in plasma. They remain for prolonged time in blood circulation [113].
In rabbits, morphological features of the lesion could be modified by the percentage of cholesterol added to the diet and the duration of the diet [111, 113]. Diets with a percentage of cholesterol of more than 2 % and given for short duration, cause hypercholesterolemia, and atherosclerotic lesions rich in foam cells originate from macrophages. In contrast of this, a diet with a low cholesterol content, and long duration causes atherosclerosis lesions, which are rich in SMCs and contain cholesterol deposits leading to atherosclerosis lesions more similar to those of humans [113]. More advanced lesions were found to be formed not with continuous but with intermittent atherogenic diets [113]. Additionally, increasing the percentage of cholesterol in the diet to more than 0.15 %, cholesterol esters were detected in the lesion [113]. Spagnoli
Acknowledgement
I apologize for not being able to cite many excellent original papers on this subject. The field has been in existence for decades so the depth and breadth of the material is very large. I am indebted to Azhar Abd Al-Jabbar Albaker for typing the manuscript.
References
- 1.
Smooth Muscle Cells in Human Coronary Atherosclerosis can Originate From Cells Administered at Marrow Transplantation. PNASCaplice N. M. Bunch T. J. Stalboerger P. G. Wang S. Simper D. Miller D. V. Russell S. J. Litzow M. R. Edwards W. D. 2003 100 8 4754 4750 - 2.
Mc Gavin D. Zachary J. F. 2007 Pathological basis of veterinary diseases. 4th ed. Mosby, Philadelphia. - 3.
Ross R. Glomest J. A. 1976a The pathogenesis of atherosclerosis. N. Engl. J. Med.,295 269 377 - 4.
Ross R. Glomset J. A. 1976b The pathogenesis of atherosclerosis. N. Engl. J. Med.,295 420 425 - 5.
Owens G. K. 1995 Regulation of differentiation of vascular smooth muscle cells. Physiol. Rev.,75 487 517 - 6.
Schwartz S. M. Heimark R. L. Mjesky M. W. 1990 Developmental mechanisms underlying pathology of arteries. Physiol. Rev., 70-1177-1209. - 7.
Owens G. K. Kumar M. S. Wamhoff B. R. 2003 Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev.,84 3 767 801 - 8.
Isogai S. Horiguchi M. Weinstein B. M. 2001 The vascular anatomy of the developing zebrafish: an atlas of embryonic and early larval development. Dev. Biol.,230 278 301 - 9.
Czirok A. Rupp P. A. Rongish B. J. Little C. D. 2002 Multi- field 3D scanning- light microscopy of early embryogenesis. J. Microsc.,206 209 217 - 10.
Hungerford J. E. Little C. D. 1999 Developmental biology of the vascular smooth muscle cell: building a multilayered vessel wall. J. Vasc. Res.,36 2 27 - 11.
Han C. I. Campbell G. Campbell J. H. 2001 Circulation bone marrow cells can contribute to neointimal formation. J. Vasc. Res.,38 113 119 - 12.
Sata M. Saiura A. Kunisato A.. Tojo A. Okada S. 2002 Hematopoietic stem cells differentiate into vascular cells in pathogenesis of atherosclerosis. Nature Medicine,8 4 403 409 - 13.
Shimizu K. Sugyama S. Aikawa M. Fukumoto Y. Rabkin E. Libby P. Mitchell R. N. 2001 Host bone- marrow cells are a source of donor intimal smooth- muscle- like cells in murine aortic transplant arteriopathy. Nature Med.,7 738 741 - 14.
Frid M. G. Kale V. A. Stenmark K. R. 2002 Mature vascular endothelium can give rise of smooth muscle cells via endothelial- mesenchymal trasndifferentiation: in vitro analysis. Cir. Res.,90 1189 1196 - 15.
Hao H. Ropraz P. Verin V. Camenzind E. Geinoz A. Pepper M. S. Gabbiani G. Bochaton-Piallat M. L. 2002 Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler. Thromb. Vasc. Biol.,22 1093 1099 - 16.
Schhulick A. H. Taylor A. J. Zuo W. Qiu C. B. Dong G. Woodward R. N. Agah R. Roberts A. B. Virmani R. Dichek D. A. 1998 Overexpression of transforming growth factor beta 1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia. Proc. Natl. Acad. Sci., USA,95 6983 6988 - 17.
Frid M. Moiseeva E. P. Stenmark K. R. 1994 Multiple phenotypically distinct smooth muscle cell population exist in the adult and developing bovine pulmonary arterial media in vivo. Cir. Res.,75 669 681 - 18.
Clowes A. W. Clowes M. M. Ingerle F. J. Reidy M. A. 1989 Kinetics of cellular proliferation after arterial injury. V. role of acute distension in the induction of smooth muscle proliferation. Lab. Invest.,60 360 364 - 19.
Clowes A. W. Clowes M. M. Reidy M. A. 1986 Kinetics of cellular proliferation after arterial injury. I. smooth muscle growth in the absence of endothelium. Lab. Invest.,49 327 333 - 20.
Clowes A. W. Reidy M. A. Clowes M. M. 1983 Mechanisms of stenosis after arterial injury. Lab. Invest.,49 208 215 - 21.
Thomas W. A. Florenting R. A. Reiner J. M. Lee W. M. Lee R. T. 1976 Alterations in population dynamics of arterial smooth muscle cells during atherogenesis. IV. evidence for a polyclonal origin of hypercholesterolemic diet- induced atherosclerotic lesions in young swine. Exp. Mol. Pathol.,24 244 260 - 22.
Bochaton _. Piallat M. L. Clowes A. W. Clowes M. M. Fishcer J. W. Redard M. Gabbiani F. Gabbiani G. 2001 Cultured arterial smooth muscle cells maintain distinct phenotypes when implanted into carotid artery. Arterioscler. Thromb. Vasc. Biol.,21 949 954 - 23.
Seidel C. L. Helgason T. Allen J. C. Wilson C. 1997 Migratory abilities of different vascular cells from the tunica media of canine vessels. Am. J. Physiol. Cell Physiol., 272: C847 C852. - 24.
Faxon D. P. Fuster V. Libby P. Beckman J. A. Hiatt W. R. Thompson R. W. Topper J. N. Annex B. H. Rundback J. H. Fabunmi R. P. Robertsn R. M. Loscalzo J. 2004 Atherosclerotic vascular disease conference writing group III: pathophysiology. Circulation,109 2617 2625 - 25.
Raines E. W. 2000 The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int. J. Exp. Pathol.,81 173 182 - 26.
The pathogenesis of atherosclerosis: a perspective for the 1990s. N. Engl. J. Med.,Ross R. (1993 362 801 809 - 27.
Galis Z. S. Khatri J. J. 2002 Matrix metalloproteinases in vascular remodeling and atherogenesis: the good; the bad, and the ugly. Circ. Res.,90 251 262 - 28.
Cho A. Graves J. Reidy M. A. 2000 Mitogen- activated protein kinase mediated matrix metalloproteinase- 9 expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol.,20 2527 2532 - 29.
Ma C. Chegini N. 1999 Regulation of matrix metalloproteinases (MMPs) and their tissue inhibitors in human myometrial smooth muscle cells by TGF-β1. Mol. Hum. Reprod.,5 950 954 - 30.
Gurjar M. V. Deleon J. Sharma R. V. Bhalla R. C. 2010a Mechanism of inhibition of matrix metalloproteinase-9 induction by NO in vascular smooth muscle cells. J. Appl. Physiol.,91 1380 1386 - 31.
Gurjar M. V. Deleaon J. Sharma R. V. Bhalla R. C. 2010b Role of reactive oxygen species in IL-1 beta- stimulate sustained ERK activation and MMD-9 induction. Am. J. Physiol. Heart. Circ. Physiol., 281: H2568 H2574. - 32.
Fabunmi R. P. Sukhova G. K. Sugiyama S. Libby P. 1998 Expression of tissue inhibitor of metalloproteinase-3 in human atheroma and regulation in lesion- associated cells: a potential protective mechanism in plaque stability. Cir. Res.,83 270 278 - 33.
Lemaitre V. Soloway P. D. D’Armiento J. 2003 Increased medial degradation with pseudo-aneurysm formation in apoliportein E-knockout mice deficient in tissue inhibitor of metalloproteinases-1. Circulation,107 333 338 - 34.
Increase expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions in human atherosclerotic plaques. J. Clin. Invest.,Galis Z. S. Sukhova G. K. Lark M. W. Libby P. (1994 94 2493 2503 - 35.
Aikawa M. Rabkin E. Voglic S. J. Shing H. Nagai R. Schoen F. J. And Libby. P. 1998a Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ. Res.,83 1015 1026 - 36.
Galis Z. S. Johnson C. Godin D. Magid R. Shipley J. M. Senior R. M. Ivan E. 2002 Targeted disruption of the matrix metalloproteinase- 9 gene impairs smooth muscle cell migration and geometrical arterial remolding. Circ. Res.,91 852 859 - 37.
Cho A. Reidy M. A. 2002 Matrix metalloproteinase- 9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res.,91 845 851 - 38.
Jormsjo S. Wuttge D. M. Sirsji A. Whatling C. Hamsten A. Stemme S. Eriksson P. 2002 Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apoliportein E-deficient mice. Am. J. Pathol.,161 939 945 - 39.
Rivard A. Andres V. 2000 Vascular smooth muscle cells proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol.,15 2 557 571 - 40.
Morice M. C. Serruys P. W. Sousa J. E. et al. 2002 A randomized comparison of sirlimus- eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med.,346 1773 1780 - 41.
Grube E. Silber S. M. Hauptmann K. E. 2001 Taxus 1: prospective randomized, double- blind comparison of NIRxTM stent coated with paclitaxel in a polymer carrier in de-novo coronary lesions compared with uncoated controls. Circulation, 104 (Suppl. II): 463 (Abstract). - 42.
Sukhanov S. Song Y. H. Delafontaine P. 2003 Biochem. Biophys. Res. Comm.,306 443 449 - 43.
Campos A. H. Zhao Y. Pollman M. J. Gibbons G. H. 2003 DNA Microarray Profiling to Identify Angiotensin-Responsive Genes in Vascular Smooth Muscle Cells- Potential Mediators of Vascular Disease.Circ. Res.,92 111 118 - 44.
Biol.,Zhang G. J. Goddard M. Shanaha C. Shapiro L.and. Bennett M. (2002 Arterioscler Thromb. Vasc 22 2030 2036 - 45.
Pullmann R. Jr Juhaszova M. de silanes I. L. Kawai T. Mazan-Mamczarz K. Halushka M. K. Gorospe M. 2005 Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA- binding protein HR. J. Biol. Chem.,280 24 22819 22826 - 46.
Fan J. Yang X. Wang W. Wood W. W. H. I. I. I. Becker K. G. Gorospe M. 2002 Global analysis of stress-regulated mRNA turnover by using cDNA arrays Proc. Natl. Acad. Sci. USA,99 10611 10616 - 47.
Wilusz C. J. Wormington M. Peltz S. W. 2001 The cap-to-tail guide to mRNA turnover.Nat. Rev. Mol. Cell Biol.,2 237 246 - 48.
Xu N. Chen C. Y. Shyu A. B. 1997 Modulation of the fate of cytoplasmic mRNA by AU-rich elements: key sequence features controlling mRNA deadenylation and decay.Mol. Cell Biol.,17 4611 4621 - 49.
Gherzi R. Lee K. Y. Briata P. Wegmuller D. Moroni C. Karin m. Chen C. Y. 2004 A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery.Mol. Cell,14 571 583 - 50.
Zhang W. Wagner B. J. Ehrenman K. Schaefer A. W. De Maria C. T. Carter D. De Haven K. Long L. Brewer G. 1993 Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1.Mol. Cell Biol.,13 7652 7665 - 51.
Stoecklin G. Colombi M. Raineri I. Leuenberger S. Mallaun M. Schmidlin M. Gross B. Lu M. Kitamura T. Moroni C. 2002 Functional cloning of BRF1, a regulator of ARE-dependent mRNA turnover.EMBO J.21 4709 4718 - 52.
EMBO J.,Wang W. Caldwell M. C. Lin S. Jurneaux H. Gorospe M. (2000 Hu R. regulates cyclin. A. cyclin B. m. R. N. A. stability during. cell proliferation. E. M. B. 19 2340 2350 - 53.
Lopez de Silanes. I. Fan J. Yang X. Potapona O. Zonderman A. B. Pizer E. S. Gorospe M. 2003 Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene,22 7146 7154 - 54.
Wang W. Yang X. Cristofalo V. J. Holbrook N. J. Borospe M. 2001 Loss of HuR is linked to reduced expression of proliferative genes during replicative senescence.Mol. Cell Biol.,21 5889 5898 - 55.
Brennan C. M. Steitz J. A. 2001 HuR and mRNA stability.Cell Mol. Life Sci.,58 266 277 - 56.
Atasoy U. Curry S. L. Lopez de Silanes. I. Shyu A. B. Casolaro V. Gorospe M. Stellato C. 2003 Regulation of eotaxin gene expression by TNF-alpha and IL-4 through mRNA stabilization: involvement of the RNA-binding protein HuR.J. Immunol.,171 4369 3478 - 57.
Fegueroa A. Cuadrado A. Fan J. Atasoy U. Muscat G. E. Munoz-Canoves P. Gorospe M. Munoz A. 2003 Role of HuR in skeletal myogenesis through coordinate regulation of muscle differentiation genes.Mol. Cell Biol.,23 4991 5004 - 58.
Van der Giessin K. Di -Marco S. Clair E. Gallouzi I. E. 2003 RNAi-mediated HuR depletion leads to the inhibition of muscle cell differentiation. J. Biol. Chem.278 47119 47128 - 59.
Wang L. Zheng J. Du Y. Huang Y. Li J. Liu B. Liu-J C. Zhu Y. Gao Y. Xu Q. Kong W. Wang X. 2010 Cartilage oligometric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with α 7 β1 integrin. Circul. Res.,106 514 524 - 60.
Lopez de Silanes. I. Zhang M. Lal A. Yang X. Gorospe M. 2004 Identification of a target RNA motif for RNA-binding protein HuR.Proc. Natl. Acad. Sci. USA,101 2978 2992 - 61.
Rudijanto A. 2007 The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med. Indones.,39 2 86 93 - 62.
Role of vascular smooth muscle cells in the pathology of atherosclerosis. Department of diabetes Beckman Research Institute of City of Hope, Duarte, CA 91010 (internet).Natarajan R. - 63.
Maytin M. Leopold J. Loscalzo J. 1999 Oxidative stress in the vasculature. Curr. Atheroscler. Rep.,1 156 164 - 64.
Zalba G. Beamount J. San Jose. G. et al. 2000 Vascular oxidant stress: molecular mechanisms and pathophysiological implications. J. Physiol. Biochem.,56 57 64 - 65.
Griendling K. K. Harruison D. G. 2001 Out, damned dot: studies of the NADPH oxidase in atherosclerosis. J. Clin. Invest.,108 1423 1424 - 66.
Tsimikas S. Palinski W. Witztum J. L. 2001 Circulating auto- antibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor deficient mice. Arterioscler. Thromb, Vasc. Biol.,21 95 1000 - 67.
Kita T. Kume N. Minami M. et al. 2001 Role of oxidized: LDL in atherosclerosis. Ann. NY. Acad. Sci.,947 199 205 - 68.
Beckman J. S. Beckman T. W. Chen J. et al. 1990 Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci., USA,87 1620 1624 - 69.
de Gaetano G. 2001 Low- dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Collaborating Group of the Primary Prevention Project. Lancet,357 89 95 - 70.
Yusuf S. Dagenais G. Pogue J. et al. 2000 Vitamin E supplementation and cardiovascular events in high- risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.,342 154 160 - 71.
Landmesser U. Harrison D. G. 2001 Oxidant stress as a marker for cardiovascular events: ox marks the spot. Circulation,104 2638 2640 - 72.
Jackson T. S. Xu A. Vita J. A. et al. 1998 Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Cir. Res.,83 916 929 - 73.
Libby P. Aikawa M. 2002 Vitamin C, collagen, and cracks in the plaque. Circulation,105 139 1398 - 74.
Libby P. 2002 Inflammation in atherosclerosis. Nature,420 868 874 - 75.
Braun M. Pietsch P. Schror K. Baumann G. Felix S. B. 1999 Cellular adhesion molecules on vascular smooth muscle cells. Cardiovasc. Res.,41 395 401 - 76.
Huo Y. Ley K. 2001 Adhesion molecules and atherogenesis. Acta Physiol. Scand.,173 35 43 - 77.
O’Brien K. D. Allen M. D. Mc Donald T. O. Chait A. Harlan J. M. Fishbein D. Mc Carty J. Ferguson M. Hudkins K. Benjamin C. D. 1993 Vascular cell adhesion molecule- 1 is expressed in human coronary atherosclerotic plaques: implication for the mode of progression of advanced coronary atherosclerosis. J. Clin. Invest.,92 945 951 - 78.
Endres M. Laufs U. Merz H. Kaps M. 1997 Focal expression of intercellular adhesion molecule- 1 in the human carotid bifurcation. Stroke,28 77 82 - 79.
Zhu Y. Hojo Ikeda. U. Takahasi M. Shimada K. J. 2002 Interaction between monocytes and vascular smooth muscle cells enhances matrix metalloproteinase- 1 production. J. Cardiovasc. Pharmacol.,36 152 161 - 80.
Weiss D. Sorescu D. Taylor W. R. 2001 Angiotensin II and atherosclerosis. Am. J. Cardiol., 87: 25c-32c. - 81.
Bornfeldt K. E. Raines E. W. Gravesm L. M. Skinner M. P. Krebs E. G. Ross R. 1995 Platelet- derived growth factor, distinct signal transudation pathways associated with migration versus proliferation. Ann. NY. Acad. Sci.,766 416 430 - 82.
Cai Q. Lanting L. Natarajan R. 2004 Growth factors induce monocyte binding to vascular smooth muscle cells: implications for monocyte retention in atherosclerosis. Am. J. Physiol. Cell Physiol., 286: C707 C714. - 83.
Margariti A. Zeng L. Xu Q. 2006 Stem cells, vascular smooth muscle cells and atherosclerosis. Histol. Histopathol.,21 979 985 - 84.
Immune mechanisms in atherosclerosis. Arterioscler. thromb.. Vasc.- Biol.,Hansson G. K. (2001 21 1876 1890 - 85.
Al-Sadi H. I. Abdullah A. K. 2011 Spontaneous atherosclerosis in free-living pigeons in Mosul area, Iraq.Pak.Vet. J.31 2 166 168 - 86.
Clarkson T. B. Prichard R. W. Netsky M. G. Lofland H. B. 1959 Atherosclerosis in pigeons: its spontaneous occurrence and resemblance to human atherosclerosis. Arch. Pathol.,68 143 147 - 87.
Simpson C. F. Harms R. H. 1968 Aortic atherosclerosis of turkeys induced by feeding of cholesterol. J. Atheroscler. Res.,10 63 75 - 88.
Moss N. S. Benditt E. P. 1970 Spontaneous and experimentally induced arterial lesions. I. an ultrastructural survey of the normal chicken aorta. Lab. Invest.,22 166 183 - 89.
Shih J. C. H. Pullman E. P. Kao K. J. 1983 Genetic selection, general characterization, and histology of atherosclerosis susceptible and resistant Japanese quail. Atherosclerosis,49 41 53 - 90.
Oku H. Toda T. Hamada Y. Kiyuna M. Chinen I. Toyomoto M. Shinjo A. 1990 Morphological and biochemical evaluation of the induction of atherosclerosis in Japanese quails. Acta Med. Nagasaki,35 81 87 - 91.
Toda T. Nihimori I. Kummerow F. A. 1983 Animal model of atherosclerosis, experimental atherosclerosis in the chicken animal model. J. Jpn. Atheroscler. Soc.,11 755 761 - 92.
Day C. G. Stafford W. W. Schurr P. E. 1977 Utility of a selected line (SEA) of the Japanese quail (Coturnix coturnix Japonica) for the discovery of new anti- atherosclerosis drug. Lab. Anim. Sci.,27 817 821 - 93.
Rapid accumulation of cholesterol in serum, liver, and aorta of Japanese quail. Poult. Sci.,Morrissey R. B. Danalbson W. E. (1977 56 2003 2008 - 94.
Wexler B. C. 1977 Spontaneous atherosclerosis in the Japanese quail. Artery,3 507 516 - 95.
Jarrold B. B. Bacon W. L. Velleman S. G. 1999 Expression and localization of the production of the proteoglycan decorin during the progression of cholesterol induced atherosclerosis in Japanese quail: Implication for interaction with collagen type I and lipoproteins. Atherosclerosis,146 299 308 - 96.
Velleman S. G. Bacon W. Whitmoyer R. Hosso S. J. 1998 Changes in distribution of glycosaminoglycans during the progression of cholesterol induced atherosclerosis in Japanese quail. Atherosclerosis,137 63 70 - 97.
Velleman S. G. Mc Cormick R. J. E:y D. Jarrold B. B. Patterson R. A. Scott C. B. Daneshvar H. Bacon W. 2001 Collagen characteristics and organization during the progression of cholesterol- induced atherosclerosis in Japanese quail. Exp. Biol. Med.,226 4 328 333 - 98.
Casale et al. 1992 studied the cellular events of quail atherosclerosis using monoclonal antibodies to alpha- actin and chicken macrophages and effectively identified the presence of SMC and macrophages, respectively, as constituents of the atherosclerotic lesions. The presence of macrophage, as well as SMC proliferation, was observed in early lesions. Although it was not possible to acertain the first cell type to be involved in the initial stages of atherosclerosis results suggested early intervention of macrophages and SMC. - 99.
Bavelaar F. J. Beynen A. C. 2004 The relation between diet, plasma cholesterol and atherosclerosis in pigeons, quails and chickens, Int. J. poult. Sci.,3 11 671 684 - 100.
Fabricant C. G. Fabricant J. 1999 Atherosclerosis induced by infection with Marek’s disease herpesvirus in chickens. Am. Heart J., 138 (5 pt2): 466-468. - 101.
Hajjar et al. 1986 demonstrated histologically that infection of normocholesterolemic, specific- pathogen- free chickens with Marek’s disease herpesvirus (MDV) lead to chronic atherosclerosis like that in humans. - 102.
Bavelaar et al. 2004 studied the possibility that feeding of α- linolenic acid instead of linoleic acid or saturated fatty acids would diminish the degree of atherosclerosis in cholesterol- fed quails. The authors concluded that a differential effect on the development of atherosclerosis of α- linolenic acid, linoleic acid and saturated fatty acids could not be demonstrated. - 103.
Frick C. Schmidt V. Cramer K. Krautwald-Junghanns M. E. Dorrestein G. M. . 2009 Characterization of atherosclerosis by histochemical and immunohistochemical methods in African grey parrots (psittacus erithacus) and amazon parrots (Amazon spp.). Avian Dis.,53 3 466 472 - 104.
Jensen T. W. Mazurm Pettigew. J. E. Perez-Mendoza V. G. Zachary J. Schook L. B. 2010 A cloned pig model for examining atherosclerosis induced by high fat, high cholesterol diets. Animal Biotechnol.,21 179 187 - 105.
Hughes G. C. et al. 2003 Translational physiology: Porcine models of human coronary artery disease: implication for preclinical trails of therapeutic angiogenesis. J. APpl. Physiol.,94 5 1689 1701 - 106.
Lee K. T. 1987 Experimental atherosclerosis in pigs. Yonsei Med. J.,28 1 1 5 - 107.
Bell F. P. Gerrity R. G. 1992 Evidence for an altered lipid metabolic state in circulation blood monocytes under condition of hyperlipemia in swine and its implications an arterial lipid- metabolism. Arterioscler. Throm.,12 2 155 162 - 108.
Yanni A. E. 2004 The laboratory rabbit: an animal model of atherosclerosis research. Lab. Anim.,38 246 256 - 109.
Bocan T. M. Muller S. B. Mazur M. J. Uhlendorf P. D. Brown E. Q. Kieft K. A. 1993 The relationship between the degree of dietary- induced hypercholesterolemia in the rabbit and atherosclerotic lesion formation. Atherosclerosis,102 9 22 - 110.
Lipid lowering by diet reduces matrix metalloproteinase activity and increase collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation,Aikawa M. Rabkin E. Voglic S. J. Shing H. Nagai R. Schoen F. J. And Libby. P. (1998b 97 2433 2444 - 111.
Kolodgie F. D. Katoces A. S. Largis E. E. Wrenn S. M. Cornhill J. F. Herderick E. E. Lee S. J. Virman R. 1996 Hypercholesterolemia in the rabbit induced by feeding graded amounts of low level cholesterol. Arteriosclerosis Thrombosis and Vascular Biology,16 1454 1464 - 112.
Role of inflammation in atherosclerosis. J. Nucl. Meo.,Spagnoli L. G. Bonanno E. Sangiorgi G. Mauriello A. (2007 48 11 1800 1815